What to know about cfDNA liquid biopsy

The test uses a blood sample rather than removing tissue. A laboratory looks within cell-free DNA, or cfDNA, for selected genetic alterations associated with tumour cells. Its usefulness depends on the clinical question, the cancer type, the amount of tumour DNA reaching the bloodstream, and the alterations covered by the test.

A detected alteration may help identify a treatment target, clarify tumour biology, or provide a marker that can be followed over time. The report must be interpreted alongside the confirmed diagnosis, scans, tissue results, current medicines, and the reason the test was requested.

A result showing no reportable alteration does not rule out cancer or prove that a tumour lacks relevant changes. Some tumours release little DNA into blood, and a test only examines the alterations included in its design. Occasionally, a blood-cell change rather than the tumour can contribute to a finding, so the oncology team may recommend confirmation with another sample.

Before the blood draw, give the team your diagnosis, previous molecular test reports, treatment history, and full medicine list. Ask what decision the test is intended to support and whether tumour tissue is already available for comparison. Follow any preparation instructions from the collection service; many cfDNA blood draws do not require special preparation.

Arrange a review of the report with the clinician who ordered it. Do not start, stop, or switch cancer treatment based on a laboratory line without clinical interpretation. If the sample contains too little tumour-derived DNA or the result does not answer the clinical question, the next step may be repeat blood testing, tissue biopsy, another molecular test, or continued assessment using scans and examinations.

The blood draw usually causes only brief local discomfort, but contact the collection team if bleeding does not settle with firm pressure or if increasing redness, swelling, warmth, or discharge develops at the puncture site. Seek urgent care for severe breathlessness, chest pain, fainting, new confusion, uncontrolled bleeding, or other rapidly worsening symptoms. These concerns require assessment rather than waiting for a liquid-biopsy result.

Ask which genes or alterations the test covers, whether it is being used to select treatment or monitor known disease, and how a positive, negative, or inconclusive result would change the plan. Also ask whether a tissue biopsy is still needed, whether a finding requires confirmation, when the report should be reviewed, and who will explain unexpected results.